Compare Ascendis Pharma A/S (ASND) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Lumen Technologies Inc — how do they compare? Ascendis Pharma A/S trades at $260.65 (market cap $16.67B), while Lumen Technologies Inc trades at $6.31 (market cap $6.58B). The key difference: Ascendis Pharma A/S is far larger — about 2.5× Lumen Technologies Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ASND | LUMN | |
|---|---|---|
Market Cap | $16.67B | $6.58B |
Sector | Health | Media |
52-Week High | $277.18 | $11.83 |
52-Week Low | $189.74 | $3.95 |
Enterprise Value | $17.04B | $18.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
LUMN stock trades at $6.375, down 3.99% today, amid a bearish technical signal and mixed earnings. The company reported a Q2 2026 loss of $0.07 per share, beating estimates, but revenue declined 9.3% year-over-year. Strategic revenues grew 14.1%, highlighting its digital transformation. CEO Kathleen Johnson purchased 100,000 shares on August 6, 2026, signaling insider confidence. Net cash flow was negative $886 million in 2025, though 2026 projections show improvement. The stock faces headwinds from high debt and legacy revenue declines.
LUMN offers a high-risk opportunity with a low P/S ratio of 0.54 and analyst consensus price target of $7.67, implying potential upside. However, persistent net losses, negative ROE of -78.94%, and $17.49 billion in long-term debt pose significant risks. Investors should weigh the digital growth potential against financial instability and cautious analyst sentiment, with 60.71% holding ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
